Current Clinical Trials
Study Information:
Study Title:
TRACER- Thrombin Receptor Antagonist for Clinical Event Reduction in ACS
Study Location:
Houston, TX
Facility Name:
Memorial hermann Heart and Vascular Institue, TMC
Study Description:
A multi-center randomized, double blind, placebo-controlled, phase 3 study to evaluate safety and efficacy. The TRA-CER study in Acute Coronary Syndrome is designed to address the effects of SCH 530348, an investigational compound which inhibit the most potent stimulus of platelet activation, thrombin, which is a driver of the clotting process. The primary objective is to evaluate the hypothesis that SCH 530348 added to standard of care will reduce the incidence of atherothrombotic ischemic events relative to standard of care alone, as measured by the composite of cardiovascular death, myocardial infarction, stroke, recurrent ischemia with rehospitalization, and urgent coronary revascularization. The Phase III TRACER Acute Coronary Syndrome trial will use an oral 40 mg loading dose and a daily 2.5 mg maintenance dose until the study is completed. Patients will be randomized to either placebo plus standard medical care (including aspirin and clopidogrel) or to TRA once daily
HSC Number:
HSC-MS-08-0049
Funding Agency/Source:
Schering Plough Research Institute (SPRI)
Subject Information:
Subject Age Range:
18 yrs or older
Inclusion/Exclusion Criteria:
The study population will comprise of moderate to high risk NSTEACS Patients. Age range: 18 yrs or older and may be of either sex and of any race. History of cardiac ischemia related symptoms of atleast 10 minutes duration ¡Ü 24 hours prior to hospital presentation. Concurrent biomarker evidence - elevated troponin I or troponin T greater than the stated upper limit of normal at the study site, or creatinine kinase-myocardial band greater than the upper limit of normal at the study site. And or concurrent electrocardiogram changes ¨C comprising new or presumably new ST-segment depression, or transient ST segment elevation in at least two contiguous leads.
Study Coordinator(s) Information:
Name:
Truc baccam
E-mail:
Truc.Baccam@uth.tmc.edu
Phone Number:
713-500-5214
Principal Investigator Information:
Name:
H. Vernon Anderson
Study Information:
Study Title:
Relax HF Study: PhosphodiesteRase-5 inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure
Study Location:
Houston, TX
Facility Name:
Memorial Hermann Heart and Vascular Institute, TMC
Study Description:
This is a double-blind, placebo controlled study testing the hypothesis that chronic PDE-5 inhibition (Sildenafil 20mg three times a day for 12 weeks followed by 60mg three times a day for 12 weeks) improves exercise capacity and clinical status in patients with heart failure and normal ejection fraction (Diastolic Heart Failure). Diastolic Heart Failure is a growing public health problem. Between 30-50% of patients with clinical Heart Failure have preserved ejection fraction. Mortality for Diastolic Heart Failure has been reported as similar to or slightly lower than that associated with Systolic Heart Failure. A recent study suggests that the prevalence of Diastolic Heart Failure is increasing and while survival among patients with Systolic Heart Failure has improved in recent years, survival for patients with Diastolic Heart Failure has not. The absence of proven therapy for Diastolic Heart Failure likely contributes to the lack of improvement in survival. Therefore, the scienti
HSC Number:
HSC-MS-08-0531
Funding Agency/Source:
National Heart, Lung and Blood Institute, National Institue of Health
Subject Information:
Subject Age Range:
Age>18
Inclusion/Exclusion Criteria:
clinical diagnosis of Heart Failure and normal ejection fraction (¡Ý50%) with current NYHA class II-IV symptoms.
Study Coordinator(s) Information:
Name:
Truc Baccam, RN
E-mail:
Truc.Baccam@uth.tmc.edu
Phone Number:
713-500-5214
Principal Investigator Information:
Name:
Dr. Deborah Meyers,MD
Study Information:
Study Title:
DOSE: Diuretic Optimization Strategies Evaluation in Acute Heart Failure
Study Location:
Houston, TX
Facility Name:
Memorial Hermann Heart and Vascular Institute, TMC
Study Description:
This is a randomized, controlled, multi-center clinical trial of patients with signs and symptoms consistent with Acute Heart Failure (AHF) within 24 hours of hospital admission. This study will evaluate dosing strategies and route of administration for a commonly used, FDA approved medication for AHF (furosemide). There is little data to guide appropriate dosing of loop diuretics during AHF therapy, and consequently practice varies widely between physicians and centers. Similarly, substantial uncertainty remains about the optimal route of administration (continuous infusion vs. intermittent bolus) for IV diuretics. Patients will be randomized to one of 4 treatment regimens defined by a 2x2 factorial treatment design: • The balance between safety and efficacy of a “low intensification” vs. a “high intensification” dosing of loop diuretics in treating AHF. • The balance between safety and efficacy of continuous infusion vs. intermittent bolus administration of loop diuretics in
HSC Number:
HSC-MS-09-0103
Funding Agency/Source:
National Institutes of Health, National Heart, Lung and Blood Institute
Subject Information:
Subject Age Range:
Age> 18 yrs
Inclusion/Exclusion Criteria:
prior clinical diagnosis of heart failure with daily home use of oral loop diuretic for at least one month. Must be identified within 24 hours of hospital admission and anticipated need for IV loop diuretics for at least 48 hours.
Study Coordinator(s) Information:
Name:
Truc Baccam, RN
E-mail:
Truc.Baccam@uth.tmc.edu
Phone Number:
713-500-5214
Principal Investigator Information:
Name:
Dr. Deborah Meyers,MD
Study Information:
Study Title:
RESPECT:The Randomised Evaluation of Stroke comparing PFO closure to Establised Current Standard of Care Treatment Trial.
Study Location:
Houston, TX
Facility Name:
Memorial Hermann Heart and Vascular Institue, TMC
Study Description:
Patent foramen Ovale is one potential suspected cause of cryptogenic stroke. Cryptogenic stroke is a stroke that occurs without normal symptoms associated with stroke. It is not known what the best treatment is to reduce the risk of a recurrent stroke. AGA Medical Corporation is conducting the RESPECT Trial to investigate whether percutaneous closure of PFO using Amplatzer PFO occluder is superior to current standard medical management in preventing recurrent cryptogenic strokes or TIA. The study is a randomized, multi-center active control trial. Patients will be randomized to either receive the AMPLATZER PFO Occluder plus medical therapy or be treated with the current medical therapy standard of care.
HSC Number:
HSC-MS-02-186
Funding Agency/Source:
AGA Medical Corp.
Subject Information:
Subject Age Range:
18-60 yrs.
Inclusion/Exclusion Criteria:
Patients with PFO who have had a ‘cryptogenic stroke’ within the last 270 days, with stroke defined as follows: acute focal neurological deficit, presumed to be due to focal ischemia, and either 1) symptoms persisting 24 hours or greater, or 2) symptoms persisting less than 24 hours but associated with MR or CT findings of a new, neuroanatomically relevant, cerebral infarct. ‘Cryptogenic stroke’ is defined as a stroke from an unknown cause. “PFO” is defined as visualization of microbubbles per TEE in the left atrium within three cardiac
Study Coordinator(s) Information:
Name:
Truc Baccam, RN
E-mail:
Truc.Baccam@uth.tmc.edu
Phone Number:
713-500-5214
Principal Investigator Information:
Name:
Dr. Richard Smalling, Md, Ph.D.
Study Information:
Study Title:
CRISP: Counterpulsation to Reduce Infarct Size Pre-PCI for Acute Myocardial Infarction—CRISP AMI
Study Location:
Houston, TX
Facility Name:
Memorial Hermann heart and Vascular Institute, TMC
Study Description:
This protocol is a multi-center, randomized, controlled study in subjects with anterior acute ST-segment–elevation myocardial infarction (STEMI), to evaluate whether counterpulsation by intra-aortic balloon (IAB), placed before mechanical reperfusion, will result in decreased infarct size. As a secondary objective, major adverse cardiac events (MACE), defined as death, reinfarction, and congestive heart failure (CHF), will be assessed to 6 months postprocedure. The study devices and therapy being studied have been cleared by the U.S. Food and Drug Administration (FDA) and in use for over 20 years. The study will be conducted at 30 clinical sites in the United States, Europe, Australia, and New Zealand and will include 300 subjects with anterior acute STEMI, defined as greater than or equal to 2 mm in 2 contiguous anterior leads or greater than or equal to 4 mm total in anterior leads, confirmed by electrocardiogram (ECG).
HSC Number:
HSC-MS-09-0033
Funding Agency/Source:
Datascope Corp.
Subject Information:
Subject Age Range:
>18yrs.
Inclusion/Exclusion Criteria:
Subjects with anterior acute ST-segment–elevation myocardial infarction (STEMI), defined as greater than or equal to 2 mm in 2 contiguous anterior leads or greater than or equal to 4 mm total in anterior leads, confirmed by electrocardiogram (ECG )
Study Coordinator(s) Information:
Name:
Mary Vooletich, RN
E-mail:
Mary.Vooletich@uth.tmc.edu
Phone Number:
713-500-6550
Principal Investigator Information:
Name:
Dr. Richard Smalling, MD. Ph.D
Study Information:
Study Title:
ALERTS: AngeLmed for Early Recognition and Treatment of STEMI
Study Location:
Houston, TX
Facility Name:
Memorial Hermann Heart and Vascular Institue, TMC
Study Description:
This is a randomized, prospective clinical investigation with blinded CORE laboratories, and an independent clinical events adjudication committee that will evaluate the effectiveness of the AngelMed Guardian System as compared with the standard of care in reducing the incidence of the composite of death, new Q-wave MI and presentation > 2 hours for thrombotic coronary occlusion events among subjects at a high-risk of recurrent myocardial infarction. The ALERTS Study will enroll up to 3000 consecutive subjects who have been identified as having a high risk of a MI due to ACS or bypass surgery. The subjects will be implanted with the Guardian System and will be randomized 1:1 to alerting and no alerting after implantation. Half of the subjects will be randomly assigned to the treatment group using the Guardian System with an EXD and alerting turned on and the other half assigned to the control group with the Guardian System alerting turned off, no EXD provided. Patients will know if the
HSC Number:
HSC-MS-09-0042
Funding Agency/Source:
Angel Medical Systems
Subject Information:
Subject Age Range:
atleast 21 yrs of age.
Inclusion/Exclusion Criteria:
The study population includes subjects presenting with high-risk acute coronary syndromes or multi-vessel coronary artery bypass surgery as a result of coronary artery disease Subjects (men or women) at least 21 years of age. Women of childbearing age must have a negative pregnancy test or confirmation of one of the following: a) Post-menopause or amenorrheic during the past year b) Surgical sterilization c) Use of effective contraceptive method
Study Coordinator(s) Information:
Name:
Mary Vooletich, RN
E-mail:
Mary.Vooletich@uth.tmc.edu
Phone Number:
713-500-6550
Principal Investigator Information:
Name:
Dr. RIchard Smalling, MD, Ph.D
Study Information:
Study Title:
IMPACT: The Impact of BIOTRONIK Home Monitoring Guided Anticoagulation on Stroke Risk in Patients with Implanted ICD and CRT-D devices
Study Location:
Houston, TX
Facility Name:
Memorial Hermann Hospital, Heart and Vascular Institue, TMC
Study Description:
Prospective, multicenter, single-blinded, and randomized (1:1 ratio) trial. This study will investigate the clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and physician-directed anticoagulation in patients with implanted dual-chamber defibrillators or cardiac resynchronization devices
HSC Number:
HSC-MS-08-0530
Funding Agency/Source:
BIOTRONIK, Inc.
Subject Information:
Subject Age Range:
>18yrs.
Inclusion/Exclusion Criteria:
Patients implanted with a BIOTRONIK Lumax HF-T / DR-T device or future legally marketed BIOTRONIK dual chamber ICD or CRT-D with HM and IEGM-Online technology and with a CHADS2 of 1 or higher. Patients in permanent AF or following anticoagulation therapy for any reason are excluded from participation.
Study Coordinator(s) Information:
Name:
Amol Rajmane
E-mail:
Amol.Rajmane@uth.tmc.edu
Phone Number:
713-500-6563
Principal Investigator Information:
Name:
Dr. Bharat Kantharia, MD
Study Information:
Study Title:
: SAPPHIRE WW: STENTING AND ANGIOPLASTY WITH PROTECTION IN PATIENTS AT HIGH-RISK FOR ENDARTERECTOMY
Study Location:
Houston, TX
Facility Name:
Memorial Hermann Hospital, Heart and Vascular Institute, TMC,
Study Description:
The primary objective of this multi-center, prospective, observational study is to estimate 30-day MAE rate of stenting (any death, stroke or any MI) with distal protection in the treatment of obstructive carotid artery disease in high-surgical risk patients with atherosclerotic disease of the carotid artery(ies). The devices to be utilized are the Cordis PRECISEÒ Nitinol Stent Systems, the Cordis ANGIOGUARD™ XP/RX Emboli Capture Guidewire (ECGW) and next generation Cordis carotid stents and EPDs as they become commercially available. The secondary objectives are to assess the consistency of 30-day MAE rates of stenting with distal protection in the treatment of obstructive carotid artery disease at high, medium and low volume center with physicians who have validated CASES training levels of 1, 2, 2P or 3 (see appendix C) and to estimate 360-day MAE (death and ipsilateral stroke) rate.
HSC Number:
HSC-MS-06-0497
Funding Agency/Source:
Cordis – A J&J Co.
Subject Information:
Subject Age Range:
>18yrs.
Inclusion/Exclusion Criteria:
The primary objective of this multi-center, prospective, observational study is to estimate 30-day MAE rate of stenting (any death, stroke or any MI) with distal protection in the treatment of obstructive carotid artery disease in high-surgical risk patients with atherosclerotic disease of the carotid artery(ies). The devices to be utilized are the Cordis PRECISEÒ Nitinol Stent Systems, the Cordis ANGIOGUARD™ XP/RX Emboli Capture Guidewire (ECGW) and next generation Cordis carotid stents and EPDs as they become commercially available. The secondary objectives are to assess the consistency of 30-day MAE rates of stenting with distal protection in the treatment of obstructive carotid artery disease at high, medium and low volume center with
Study Coordinator(s) Information:
Name:
Mary Vooletich, RN
E-mail:
Mary.Vooletich@uth.tmc.edu
Phone Number:
713-500-6550
Principal Investigator Information:
Name:
Dr. Rochard Smalling, MD, Ph.D
Study Information:
Study Title:
VEST/PREDICTS: Vest prevention of Early Sudden death Trial (VEST) and PREDiction of ICD Therapies Study (PREDICTS)
Study Location:
Houston, TX
Facility Name:
Memorial Hermann Hospital, Heart and Vascular Institue, TMC,
Study Description:
While implantable cardioverter-defibrillators (ICDs) have had some impact in reducing the nearly 500,000 annual sudden cardiac deaths (SCD) in the US, our current treatment strategy is still limited. Recent studies have demonstrated a very high rate of sudden cardiac death in the first 2 months following a myocardial infarction (MI), particularly in participants with depressed left ventricular function. Nonetheless, because no study to date has demonstrated a mortality benefit of implanting an ICD within 40 days immediately after MI, the current practice is to wait at least 40 days after an MI. This leaves an unprotected, vulnerable period of increased sudden death risk prior to ICD implantation. Therefore, two deficiencies in our current treatment strategy are 1) the untreated high sudden death rate in the early post-MI period and 2) the non-specific nature of EF to predict spontaneous ventricular arrhythmias and ICD shocks. To address these important deficiencies, we have designed th
HSC Number:
HSC-MS-08-0367
Funding Agency/Source:
VEST: 60 days , PREDICTS: 5 years (average); minimum 3 years
Subject Information:
Subject Age Range:
atleast 18 yrs. old
Inclusion/Exclusion Criteria:
Participants hospitalized with an MI with left ventricular ejection fraction (LVEF) of <35% who are at least 18 years old
Study Coordinator(s) Information:
Name:
Gerrie Wynn
E-mail:
Gerrie.wynn@uth.tmc.edu
Phone Number:
713-500-6889
Principal Investigator Information:
Name:
Dr. Anne Dougherty, MD
CV:
Information on the Principal Investigator
Study Information:
Study Title:
HEARTS: Houston Early Age Risk Testing & Screening
Study Location:
Houston, TX
Facility Name:
Memorial Hermann hospital, Heart and Vascular Institue, TMC
Study Description:
Sudden cardiac arrest (SCA) occurs in ~ 1/100,000 students/year. Following SCA, 90% die; of the remainder, 33% have permanent neurological damage. Automated External Defibrillators (AED’s) help prevent death if SCA occurs & are mandated in Texas schools. We estimate that~ 1:50-1:100 young children in US have an undiagnosed heart condition. Family doctors were unaware of any underlying cardiac abnormality in >=95% of children who die suddenly i.e. screening by history & physical examination alone are not sufficient to detect many critical cardiovascular abnormalities in young children. There is no standard screening of school or college athletes, nor are there approved certification procedures for professionals who perform screening examinations. In Italy, since the introduction of a nationwide systematic cardiovascular screening, the incidence of SCA in young competitive athletes has substantially declined when compared to unscreened non-athletes. By identifying sixth grade students wi
HSC Number:
HSC-MS-08-0518
Funding Agency/Source:
Memorial Hermann Foundation
Subject Information:
Subject Age Range:
Sixth Grade students from hoouston Schools
Inclusion/Exclusion Criteria:
1500 sixth grade students in schools in the city of Houston are administered cardiovascular screening which will include a (1) selfadministered questionnaire, (2) cardiac physical examination, (3) electrocardiogram (EKG), and a (4) limited 2-dimensional and Doppler echocardiogram (2-D echo) in a time efficient manner by trained and licensed healthcare workers.
Study Coordinator(s) Information:
Name:
Teri Yover
E-mail:
Teri.D.Yover@uth.tmc.edu
Phone Number:
713-500-5892
Principal Investigator Information:
Name:
Dr. John Higgins, MD
CV:
Information on the Principal Investigator
Study Information:
Study Title:
PATCAR: Pre-Hospital Administration of Lytic with Urgent Culprit Artery Revascularization
Study Location:
Houston, TX
Facility Name:
Memorial Hermann Hospital, Heart and Vascular Institue, TMC
Study Description:
Acute myocardial infarction (MI) continues to be the leading cause of death in the US. Neither intravenous (IV) reduced dose fibrinolysis nor primary coronary stenting has proven to be an ideal therapeutic regimen. The combination of techniques including pre-hospital reduced dose fibrinolysis followed by emergency cardiac catheterization may be an optimal therapeutic regimen for patients with ST elevation myocardial infarction (STEMI). Preliminary results by our group and colleagues from four other high volume centers suggest that the 30-day mortality in acute MI could be reduced from 6-10% to less than 4% with a coordinated system of care similar to that practiced for trauma patients across the country today. No large scale experience in this country or Europe with pre-hospital reduced dose fibrinolysis followed by emergency coronary angiography, and stenting has been reported to date. A coordinated strategy for treatment of all Acute MI patients in the US should significantly re
HSC Number:
HSC-MS-03-021
Funding Agency/Source:
NA
Subject Information:
Subject Age Range:
18 yrs. and older
Inclusion/Exclusion Criteria:
Study population: 1) Ischemic discomfort (squeezing, crushing, or pressure, sub-sternal, unrelated to breathing or movement), epigastric discomfort or pre-syncopal symptoms with diaphoresis, lasting > 30 minutes 2) ST elevation > 0.1 mV in 2 or more contiguous limb leads or > 0.2 mV in 2 or more contiguous pre-cordial leads. 3) Less than 6 hr after onset of sustained chest pain. 4) Age 18 years or older
Study Coordinator(s) Information:
Name:
Mary Vooletich, RN
E-mail:
Mary.Vooletich@uth.tmc.edu
Phone Number:
713-500-6550
Principal Investigator Information:
Name:
Dr. Richard Smalling, MD, Ph.D
CV:
Information on the Principal Investigator
Study Information:
Study Title:
PROTECT II: A prospective, multi-center, randomized controlled trial of the IMPELLA® RECOVER® LP 2.5 System versus Intra Aortic Balloon Pump (IABP) in Patients Undergoing Non Emergent High Risk PCI
Study Location:
Houston, TX
Facility Name:
Memorail Hermann Heart & Vascular Institute, TMC
Study Description:
The intra-aortic balloon pump (IABP) is an established additional support to pharmacologic treatment for mechanical complications after myocardial infarction, cardiogenic shock, and cardiac surgery. However, because the IABP does not actively unload the left ventricle, it requires a stable cardiac rhythm and residual cardiac function to be effective. In case of a circulatory hemodynamic collapse during high risk PCI for example, IABP support is unlikely to reverse shock and restore normal circulation. In an attempt to address some of these limitations, ABIOMED developed a miniaturized catheter-based cardiac assist device, the IMPELLA RECOVER LP 2.5, that pumps up to 2.5 l/min of blood from the left ventricle to the systemic circulation across the aortic valve. PROTECT I trial in a restricted patient population has shown some of the potential benefit of the IMPELLA pump for these very sick high risk patients. ABIOMED would like to conduct a prospective controlled randomized trial to dem
HSC Number:
HSC-MS-08-0080
Funding Agency/Source:
Abiomed , Inc
Subject Information:
Subject Age Range:
18 yr< age< 90 yr
Inclusion/Exclusion Criteria:
The study population will consist of high risk subjects (18< age< 90) indicated for nonemergent percutaneous treatment of at least one de novo or restenotic lesion in a native coronary vessel or bypass graft.
Study Coordinator(s) Information:
Name:
Yalonda Stiner
E-mail:
Yalonda.S.Stiner@uth.tmc.edu
Phone Number:
713-500-6275
Principal Investigator Information:
Name:
Dr. Ali Denktas, MD
Study Information:
Study Title:
RECOVER II Trial: A Prospective Randomized Trial Investigating the Use of the IMPELLA® RECOVER® LP 2.5 System in Patients with Acute Myocardial Infarction Induced Hemodynamic Instability
Study Location:
Houston, TX
Facility Name:
Memorail Hermann Heart & Vascular Institute, TMC
Study Description:
The main objective of this study is to assess the safety and effectiveness of the IMPELLA® RECOVER® LP 2.5 System in treating patients undergoing percutaneous coronary intervention (PCI) with acute myocardial infarction (AMI) induced hemodynamic instability. The primary endpoint will be the observed reduction of Major Adverse Event (MAE) in the IMPELLA RECOVER LP 2.5 through 30 days or hospital discharge, whichever is longer, as compared to the control group treated with IABP. Study follow-up will be complete when all subjects have been followed up to three months. The Major Adverse Event rate for IMPELLA will be tested for superiority to the IABP group.
HSC Number:
HSC-MS-0404
Funding Agency/Source:
Abiomed , Inc
Subject Information:
Subject Age Range:
18 yr< age< 90 yr
Inclusion/Exclusion Criteria:
The study population(18
Study Coordinator(s) Information:
Name:
Yalonda Stiner
E-mail:
Yalonda.S.Stiner@uth.tmc.edu
Phone Number:
713-500-6275
Principal Investigator Information:
Name:
Dr. Ali Denktas, MD
Study Information:
Study Title:
Century Health Study
Study Location:
Houston, Tx
Facility Name:
University of Texas Medical School
Study Description:
The Century Health Study is a collaboration between UT Medical School and Memorial Hermann Hospital looking at advanced treatment for patients with documented heart disease and those who have multiple risk factors for heart disease. It is a randomized 5 year study testing two strategies for treating heart disease. One study group will be scheduled for dietary and lifestyle assessments once a year throughout the study, the other group will be scheduled for dietary and lifestyle counseling 5 times during the first year and twice a year thereafter. Patients who are referred for a nuclear stress test may qualify for the study. All patients will undergo a cardiac PET scan at the first visit, at 2 and 5 years and basic chemistry and cholesterol levels will be drawn. At every visit, study participants will see a study nurse, cardiologist, and a dietician. The visits, testing, counseling, and lab work are provided at no cost to the participant. This program is meant to support and not to subs
More Information:
website
HSC Number:
HSC-MS-08-0312
Funding Agency/Source:
Weatherhead Foundation
Subject Information:
Subject Age Range:
40 years of age and above
Inclusion/Exclusion Criteria:
Inclusion criteria: Multiple cardiovascular risk factors such as current or recent smoking, diabetes, high cholesterol, high blood pressure, positive family history of heart disease less than 60 years of age; body mass index of 35 or less; calcium score of >400; History of coronary artery bypass surgery; coronary angioplasty and/or stent procedure; documented heart disease; chest pain symptoms. No history of liver disease or kidney disease
Study Coordinator(s) Information:
Name:
Catey Carter, RN
E-mail:
catharine.v.carter@uth.tmc.edu
Phone Number:
713-500-5200
E-mail:
ms.century@uth.tmc.edu
Phone Number:
713-500-5200
Principal Investigator Information:
Name:
Stefano Sdringola, MD
HOME
http://med.uth.tmc.edu
UT Physicians
UTHSC-Houston
UT Medical School
http://med.uth.tmc.edu
UT Physicians
UTHSC-Houston
UT Medical School
